Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy

Abstract

Background Germ cell tumor (GCT) patients with unfavourable response to first-line therapy still lack reliable diagnostic and effective treatment Detailed correlation of total extracellular DNA (ecDNA), other DNA species and endogenous DNase levels in GCT patients’ plasma and translational utility remains under- investigated. Study aim and methods We determined DNase plasma levels, ecDNA of different subcellular origin and neutrophil extracellular trap (NETs)-associated markers. Next, we determined the associations of these parameters with a level of the DNA damage, immune inflammatory index, specific immune cell subpopulations in a cohort of the 117 GCT patients and 19 matched healthy donors (HDs). Moreover, we investigated how exogenous DNase affects antitumor effect of cisplatin in GCT model of cisplatin-resistant embryonal carcinoma NTERA-2 CisR. Results Our data demonstrate that high level of ecDNA and low level of DNase in GCT patients’ plasma is associated with significantly worse progression-free survival and overall survival. The level of the plasma ecDNA was five times higher in the GCT patients compared to the HDs. The patients with higher total ecDNA and ncDNA, but not mtDNA, had inferior PFS and OS compared to the patients with lower ecDNA (all p < 0.05). There was an inverse correlation between plasma DNase and ecDNA levels, and between plasma DNase level and clinical outcome. Importantly, combined treatment with cisplatin and human recombinant DNase I delayed growth of the NTERA-2 CisR xenografts and prolonged animal survival. Importantly, Pulmozyme significantly reduced intratumoral microvascular density in our preclinical model. Conclusion Our data confirm the association between low plasma DNase activity and worse overall survival for the first time in GCT patients. This study further validated the prognostic value of total ecDNA in GCT patients. More importantly, our preclinical data substantiated beneficial effect of Pulmozyme combination with cisplatin treatment to improve the therapeutic outcome in refractory disease.